Determination of the hemoglobin F program in human progenitor-derived erythroid cells

Area of Science:

• Hematology
• Molecular Biology
• Genetics

Background:

• Fetal hemoglobin (HbF) production normally switches off after birth.
• Non-deletion hemoglobinopathies are genetic blood disorders affecting hemoglobin synthesis.
• Understanding HbF regulation is crucial for managing hemoglobinopathies.

Purpose of the Study:

• To quantify fetal hemoglobin (HbF) content in erythroid cells derived from various human and simian progenitors.
• To investigate the 'HbF program'—the inherent capacity to produce HbF in erythroid cells.
• To explore variability in HbF production in patients with nondeletion hemoglobinopathies.

Main Methods:

• Radioligand immunoassay was used to measure absolute HbF content in erythroid cells.
• Erythroid progenitors, including burst-forming units (BFU-E) and colony-forming units (CFU-E), were cultured in vitro.
• HbF levels were analyzed in cells derived from normal human/simian subjects and patients with nondeletion hemoglobinopathies.

Main Results:

• HbF content varied significantly (0.7%–19.6%) across different erythroid progenitor types.
• HbF production was generally consistent across human progenitor types but varied greatly in nondeletion hemoglobinopathy patients.
• Erythropoietin influenced erythroid colony size and number but not the HbF program; simian progenitors showed higher, maturity-dependent HbF levels.

Conclusions:

• The switch-off of gamma-chain production appears to occur after the CFU-E stage.
• The 'HbF program' in nondeletion hemoglobinopathy patients exhibits substantial inter-individual variability.
• The molecular mechanisms underlying this variable HbF program require further investigation.